Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie has launched a Phase 2 multicenter, randomized study to evaluate targeted therapies for adults with active psoriatic arthritis. Officially titled ‘A Phase 2 Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult Subjects With Active Psoriatic Arthritis,’ the study aims to assess the efficacy and safety of risankizumab and lutikizumab, either as monotherapies or in combination, in alleviating symptoms of psoriatic arthritis, a condition characterized by joint pain, stiffness, and swelling.
The study involves three treatment arms: lutikizumab monotherapy, risankizumab monotherapy, and a combination of both. These interventions are administered via subcutaneous injections, targeting the reduction of disease symptoms and improving patient outcomes.
This interventional study follows a randomized, parallel assignment model with no masking, focusing primarily on treatment. Approximately 120 participants will be enrolled across 40 global sites, providing a comprehensive analysis of the therapies’ impacts.
The study commenced on April 11, 2025, with primary completion and estimated study completion dates yet to be announced. The latest update was submitted on July 29, 2025, indicating ongoing recruitment and progress.
AbbVie’s study could significantly influence its stock performance by potentially expanding its portfolio of effective treatments for psoriatic arthritis, a competitive market with several key players. Successful outcomes could enhance investor confidence and position AbbVie favorably against competitors.
The study is actively recruiting, with further details available on the ClinicalTrials portal.